Research ArticleDiabetes

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator

See allHide authors and affiliations

Science Translational Medicine  16 Jan 2019:
Vol. 11, Issue 475, eaau3441
DOI: 10.1126/scitranslmed.aau3441

Article Information

vol. 11 no. 475

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 2, 2017
  • Resubmitted June 7, 2018
  • Accepted for publication December 10, 2018
  • .

Author Information

  1. Adrian Vella1,
  2. Jennifer L. R. Freeman2,
  3. Imogene Dunn2,
  4. Kit Keller2,
  5. John B. Buse3 and
  6. Carmen Valcarce2,*
  1. 1Division of Endocrinology and Diabetes, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
  2. 2vTv Therapeutics Inc. and vTv Therapeutics LLC, High Point, NC 27265, USA.
  3. 3Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.
  1. *Corresponding author. Email: cvalcarce{at}vtvtherapeutics.com

Altmetric

Article usage

Article usage: January 2019 to January 2021

AbstractFullPdf
Jan 20196779824429
Feb 201996610164
Mar 20195787566
Apr 20194245440
May 20193984922
Jun 20194656523
Jul 20196132713
Aug 201910983226
Sep 201910425928
Oct 20199524723
Nov 20197253128
Dec 2019466338
Jan 202010815645
Feb 20201625899
Mar 2020922358
Apr 2020521896
May 2020622651
Jun 20201123455
Jul 2020321531
Aug 20201013353
Sep 20201614958
Oct 20201015661
Nov 20202516660
Dec 2020814550
Jan 2021127649

Stay Connected to Science Translational Medicine

Navigate This Article